The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Reviewing the use of extracorporeal photopheresis in treating CTCL
Francine Foss, MD, Yale University School of Medicine, New Haven, CT, discusses the role of extracorporeal photopheresis (ECP) in the treatment of patients with cutaneous T-cell lymphoma (CTCL), especially in Sézary syndrome. A retrospective analysis of patients receiving ECP was performed to assess which patient characteristics affected outcomes, and Prof. Foss emphasizes how the data can refine the use of ECP within the treatment landscape, especially when it is combined with interferons or retinoids. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
